U.K. Is First to Approve a CRISPR-Based Therapy, Covering Two Blood Disorders - MedCity News
MedCity News
|
Summary
UK first to approve CRISPR-based therapy, Casgevy, for treating blood disorders sickle cell disease and beta thalassemia. Vertex Pharmaceuticals and CRISPR Therapeutics commercialize gene-edited, one-time treatment. MHRA approval given after trial results indicate reduced pain, transfusion needs; side effects comparable to similar procedures. Post-approval research required; authorization potentially renewed annually. Upcoming FDA decisions await for US approval.
